Literature DB >> 8099741

Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.

B A Ellenbroek1.   

Abstract

Forty years after the first clinical report on the effectiveness of chlorpromazine in psychiatric patients, neuroleptic drugs are still the most widely used drugs in the treatment of schizophrenia. Indeed, there are no other drugs which have proven to be as effective in the treatment of this severe psychiatric disorder. Yet, there are still many unresolved problems relating to neuroleptic drugs. The present review gives a comprehensive overview of our knowledge (and our lack of knowledge) with respect to the clinical and preclinical effects of neuroleptic drugs and tries to integrate this knowledge in order to identify the neuronal mechanisms underlying the therapeutic and side effects of neuroleptic drugs.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8099741     DOI： 10.1016/0163-7258(93)90036-d

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  17 in total

Review 1.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.

Authors:  Barbara Bricker; Dinithia Sampson; Seth Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2014-02-21       Impact factor: 3.533

5.  Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells.

Authors:  S Y Choi; Y H Kim; Y K Lee; K T Kim
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

6.  The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine.

Authors:  A R Cools; E P Prinssen; B A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

7.  Phencyclidine-induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine.

Authors:  I M White; G S Flory; K C Hooper; J Speciale; D A Banks; G V Rebec
Journal:  J Neural Transm Gen Sect       Date:  1995

8.  Amphetamine, cocaine, and dizocilpine enhance performance on a lever-release, conditioned avoidance response task in rats.

Authors:  I M White; J R Christensen; G S Flory; D W Miller; G V Rebec
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.

Authors:  Haiyun Xu; Hong-Ju Yang; Bryan McConomy; Ronald Browning; Xin-Min Li
Journal:  Front Behav Neurosci       Date:  2010-03-18       Impact factor: 3.558

Review 10.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.